Treatment of Mild-to-Moderate Facial Seborrheic Dermatitis in Adults

This protocol addresses adults presenting with mild-to-moderate seborrheic dermatitis of the face and/or body — a common and clinically distinct presentation that calls for a targeted topical treatment strategy.

Clinical Scenario

The patient is an adult with mild-to-moderate seborrheic dermatitis localised to facial and/or body skin surfaces. Facial seborrheic dermatitis is the central feature of this presentation. The primary treatment goals are reduction of erythema and scaling in the affected areas.

Treatment Approach

Topical antifungal and anti-inflammatory agents are strongly recommended as first-line therapy for this presentation. The complete protocol specifies which agents apply and how they are sequenced.

Full agent selection, regimen structure, and any additional steps are available in the complete protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.2147/CCID.S284671

The use of topical antifungal (KTZ, ciclopirox, clotrimazole) and antiinflammatory (desonide, hydrocortisone, lithium succinate/gluconate, topical pimecrolimus/tacrolimus) agents is strongly recommended for mild-to-moderate SD on face and/or body areas (Table 2).
Recommended topical therapeutic options for mild-to-moderate facial and/or body areas SD include 2% KTZ (Level A), FDA approved in patients aged 12 years or older as cream or gel in 2002 and 2006, respectively.
Their recommended frequency of use is twice daily over 4–8 weeks in SD acute phase or once-weekly for 12 weeks as maintenance therapy.

View source ↗